LGC Ltd:製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】LGC Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C10819)・商品コード:DATA904C10819
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:38
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
LGC Ltd (LGC), formerly LGC (Teddington) Ltd is a life sciences measurement and testing company that offers reference materials, genomics solutions and analytical testing products and services. The company’s products comprise DNA extraction instrumentation, DNA extraction kits, Douglas scientific, genotyping chemistry, genotyping instruments, genotyping libraries and others. It offers services such as genotyping, consultancy, consumer product testing, digital forensic investigation, DNA and RNA extraction services, DNA sequencing, drug and alcohol testing, drug development services, food and agricultural analytical services and others. The company caters to agrigenomics, forensic science, food, government and academia; human genomics, pharma and healthcare and sports sectors. It serves its clients in the UK and abroad. LGC is headquartered in Teddington, the UK.

LGC Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
LGC Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
LGC Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
LGC Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
LGC Ltd, Medical Devices Deals, 2012 to YTD 2018 9
LGC Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
LGC Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
LGC Genomics To Acquire Bioanalytical Sciences Business Of Quotient BioResearch 11
Venture Financing 12
Lucigen Raises USD2.2 Million in Venture Financing 12
Lucigen Raises USD1.95 Million in Venture Financing 13
Lucigen Raises US$1.7 Million In Venture Financing 14
Private Equity 15
KKR to Acquire LGC from Bridgepoint 15
Partnerships 16
Lucigen Enters into Distribution Agreement with Illumina 16
Lucigen Enters into Distribution Agreement with Sigma-Aldrich 17
EnviroLogix Enters Into Distribution Agreement With Douglas Scientific 18
Lucigen Enters Into Distribution Agreement With Research Corporation Technologies For Endotoxin Free CleanColi Expression System 19
Link Technologies Enters Into Distribution Agreement With GeneDesign 20
ChromaDex Enters Into Distribution Agreement With LGC Standards For LoGiCal Reference Standards 21
EnviroLogix Enters Into Co-Development Agreement With Douglas Scientific 22
Life Technologies Enters Into Co-Marketing Agreement With Douglas Scientific 23
Licensing Agreements 24
LGC Enters into Licensing Agreement with Keygene 24
Biosearch Technologies Enters Into Licensing Agreement With Rutgers University For turboFISH Technology 25
Biosearch Technologies Enters Into Licensing Agreement With University of Medicine and Dentistry of New Jersey For Nucleic Acid Probe Technology 26
Acquisition 27
LGC Acquires Axolabs 27
LGC to Acquire Biosearch Technologies 28
Biosearch Technologies Acquires Majority Stake In LightSpeed Genomics 29
LGC Ltd – Key Competitors 30
LGC Ltd – Key Employees 31
LGC Ltd – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Joint Venture 33
Recent Developments 34
Corporate Communications 34
Sep 22, 2017: Dr. Juergen Mueller joins LGC as Commercial and Strategic Development Director, Oligo-therapeutics 34
Legal and Regulatory 35
Jul 03, 2018: NML awarded ISO17025 accreditation for digital PCR-based quantification of DNA 35
Product News 36
Jul 05, 2017: Meridian2 delivers high throughput liquid handling for PCR 36
Jan 16, 2017: Hydrocycler2 delivers high throughput thermal cycling for PCR 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
LGC Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
LGC Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 2
LGC Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
LGC Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
LGC Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
LGC Ltd, Medical Devices Deals, 2012 to YTD 2018 9
LGC Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
LGC Genomics To Acquire Bioanalytical Sciences Business Of Quotient BioResearch 11
Lucigen Raises USD2.2 Million in Venture Financing 12
Lucigen Raises USD1.95 Million in Venture Financing 13
Lucigen Raises US$1.7 Million In Venture Financing 14
KKR to Acquire LGC from Bridgepoint 15
Lucigen Enters into Distribution Agreement with Illumina 16
Lucigen Enters into Distribution Agreement with Sigma-Aldrich 17
EnviroLogix Enters Into Distribution Agreement With Douglas Scientific 18
Lucigen Enters Into Distribution Agreement With Research Corporation Technologies For Endotoxin Free CleanColi Expression System 19
Link Technologies Enters Into Distribution Agreement With GeneDesign 20
ChromaDex Enters Into Distribution Agreement With LGC Standards For LoGiCal Reference Standards 21
EnviroLogix Enters Into Co-Development Agreement With Douglas Scientific 22
Life Technologies Enters Into Co-Marketing Agreement With Douglas Scientific 23
LGC Enters into Licensing Agreement with Keygene 24
Biosearch Technologies Enters Into Licensing Agreement With Rutgers University For turboFISH Technology 25
Biosearch Technologies Enters Into Licensing Agreement With University of Medicine and Dentistry of New Jersey For Nucleic Acid Probe Technology 26
LGC Acquires Axolabs 27
LGC to Acquire Biosearch Technologies 28
Biosearch Technologies Acquires Majority Stake In LightSpeed Genomics 29
LGC Ltd, Key Competitors 30
LGC Ltd, Key Employees 31
LGC Ltd, Other Locations 32
LGC Ltd, Subsidiaries 32
LGC Ltd, Joint Venture 33

List of Figures
LGC Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
LGC Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
LGC Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
LGC Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
LGC Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
LGC Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
LGC Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★調査レポート[LGC Ltd:製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C10819)販売に関する免責事項を必ずご確認ください。
★調査レポート[LGC Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆